Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer
- PMID: 30778799
- DOI: 10.1007/s10120-019-00938-8
Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer
Erratum in
-
Correction to: Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer.Gastric Cancer. 2019 Jul;22(4):906. doi: 10.1007/s10120-019-00955-7. Gastric Cancer. 2019. PMID: 30963319
Abstract
Background: It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy.
Methods: In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station.
Results: The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5-80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices.
Conclusions: Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer.
Keywords: Proximal gastrectomy; Proximal gastric cancer; Therapeutic effect.
References
-
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. https://doi.org/10.1002/ijc.29210 . (Epub 2014/09/16). - DOI
-
- Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 2010;46(6):1101–10. https://doi.org/10.1016/j.ejca.2010.0 . - DOI - PubMed
-
- Deans C, Yeo MS, Soe MY, Shabbir A, Ti TK, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35(3):617 – 24. https://doi.org/10.1007/s00268-010-0935-0 . (Epub 2011/01/05). - DOI - PubMed
-
- Takiguchi N, Takahashi M, Ikeda M, Inagawa S, Ueda S, Nobuoka T, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer. 2015;18(2):407–16. https://doi.org/10.1007/s10120-014-0377-8 . (Epub 2014/05/08). - DOI
-
- Wen L, Chen XZ, Wu B, Chen XL, Wang L, Yang K, et al. Total vs. proximal gastrectomy for proximal gastric cancer: a systematic review and meta-analysis. Hepatogastroenterology. 2012;59(114):633–40. https://doi.org/10.5754/hge11834 . (Epub 2012/02/14). - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical